Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
CNS Pharmaceuticals, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2035-11-17 | Direct | 1,517 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 1,517 · Balance 1,517 F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3: Issued in connection with the reporting person's employment with the Company. F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").
F2: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001900452-26-000001 · form4-06152026_040607.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 22:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 1,517 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001683168-25-008566 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2035-11-17 F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:16 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001415889-25-016240 · form4-06092025_080604.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:40 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0001415889-24-016102 · form4-06082024_010641.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:51 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002285 · ownership.xml · derivative · entry 2 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,074 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. F1 · derivative.expiration_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:51 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 17,500 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002285 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,574 Underlying: Common Stock · 17,500 shares Expires 2034-04-08 F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 22:21 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 16,551 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-006680 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,914 Underlying: Common Stock · 18,650 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Oct 12, 2023 22:00 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 9,475 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-007108 · ownership.xml · derivative · entry 2 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,074 Underlying: Common Stock · 9,475 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F3 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 14, 2023 Filed Oct 12, 2023 22:00 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 6,500 | Not disclosed Strike: $2.27 | Not disclosed |
DisclosureSEC source: 0001683168-23-007108 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,599 Underlying: Common Stock · 6,500 shares Expires 2033-09-14 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:48 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001610717-23-000142 · form4.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 21:11 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 8,300 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001683168-23-003078 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2023-05-05 F2 · price: The options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or May 5, 2023, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 05, 2023 Filed Aug 11, 2023 01:14 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 2,099 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001683168-23-005536 · ownership.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,099 Underlying: Common Stock · 2,099 shares Expires 2033-05-05 F2 · price: The options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or May 5, 2023, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:36 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001567619-22-012777 · doc1.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 22:06 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001567619-22-001370 · doc1.xml · derivative · entry 1 Cockroft Bettina M. · CIK 0001900452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from January 19, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.